Hepatic Insulin Clearance: Mechanism and Physiology

被引:189
作者
Najjar, Sonia M. [1 ,2 ]
Perdomo, German [3 ]
机构
[1] Ohio Univ, Dept Biomed Sci, Athens, OH 45701 USA
[2] Ohio Univ, Heritage Coll Osteopath Med, Diabet Inst, Athens, OH 45701 USA
[3] Univ Burgos, Dept Ciencias Salud, Burgos, Spain
基金
美国国家卫生研究院;
关键词
DEGRADING ENZYME-ACTIVITY; CELL-ADHESION MOLECULE-1; FREE FATTY-ACIDS; GROWTH-FACTOR-I; RECEPTOR-MEDIATED INTERNALIZATION; CARCINOEMBRYONIC ANTIGEN FAMILY; SITE-DIRECTED MUTAGENESIS; RAT-LIVER; BETA-CELL; ECTO-ATPASE;
D O I
10.1152/physiol.00048.2018
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Upon its secretion from pancreatic beta-cells, insulin reaches the liver through the portal circulation to exert its action and eventually undergo clearance in the hepatocytes. In addition to insulin secretion, hepatic insulin clearance regulates the homeostatic level of insulin that is required to reach peripheral insulin target tissues to elicit proper insulin action. Receptor-mediated insulin uptake followed by its degradation constitutes the basic mechanism of insulin clearance. Upon its phosphorylation by the insulin receptor tyrosine kinase, carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) takes part in the insulin-insulin receptor complex to increase the rate of its endocytosis and targeting to the degradation pathways. This review summarizes how this process is regulated and how it is associated with insulin-degrading enzyme in the liver. It also discusses the physiological implications of impaired hepatic insulin clearance: Whereas reduced insulin clearance cooperates with increased insulin secretion to compensate for insulin resistance, it can also cause hepatic insulin resistance. Because chronic hyperinsulinemia stimulates hepatic de novo lipogenesis, impaired insulin clearance also causes hepatic steatosis. Thus impaired insulin clearance can underlie the link between hepatic insulin resistance and hepatic steatosis. Delineating these regulatory pathways should lead to building more effective therapeutic strategies against metabolic syndrome.
引用
收藏
页码:198 / 215
页数:18
相关论文
共 223 条
[1]   Deletion of Insulin-Degrading Enzyme Elicits Antipodal, Age-Dependent Effects on Glucose and Insulin Tolerance [J].
Abdul-Hay, Samer O. ;
Kang, Dongcheul ;
McBride, Melinda ;
Li, Lilin ;
Zhao, Ji ;
Leissring, Malcolm A. .
PLOS ONE, 2011, 6 (06)
[2]   CEACAM1 modulates epidermal growth factor receptor-mediated cell proliferation [J].
Abou-Rjaily, GA ;
Lee, SJ ;
May, D ;
Al-Share, QY ;
DeAngelis, AM ;
Ruch, RJ ;
Neumaier, M ;
Kalthoff, H ;
Lin, SH ;
Najjar, SM .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (07) :944-952
[3]   IDENTIFICATION OF RESIDUES IN THE INSULIN MOLECULE IMPORTANT FOR BINDING TO INSULIN-DEGRADING ENZYME [J].
AFFHOLTER, JA ;
CASCIERI, MA ;
BAYNE, ML ;
BRANGE, J ;
CASARETTO, M ;
ROTH, RA .
BIOCHEMISTRY, 1990, 29 (33) :7727-7733
[4]   CELLULAR-LOCALIZATION OF INSULIN-DEGRADING ENZYME IN RAT-LIVER USING MONOCLONAL-ANTIBODIES SPECIFIC FOR THIS ENZYME [J].
AKIYAMA, H ;
SHII, K ;
YOKONO, K ;
YONEZAWA, K ;
SATO, S ;
WATANABE, K ;
BABA, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 155 (02) :914-922
[5]   Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance [J].
Al-Share, Qusai Y. ;
DeAngelis, Anthony M. ;
Lester, Sumona Ghosh ;
Bowman, Thomas A. ;
Ramakrishnan, Sadeesh K. ;
Abdallah, Simon L. ;
Russo, Lucia ;
Patel, Payal R. ;
Kaw, Meenakshi K. ;
Raphael, Christian K. ;
Kim, Andrea Jung ;
Heinrich, Garrett ;
Lee, Abraham D. ;
Kim, Jason K. ;
Kulkarni, Rohit N. ;
Philbrick, William M. ;
Najjar, Sonia M. .
DIABETES, 2015, 64 (08) :2780-2790
[6]  
ANSORGE S, 1984, BIOMED BIOCHIM ACTA, V43, P39
[7]   Variability of Directly Measured First-Pass Hepatic Insulin Extraction and Its Association With Insulin Sensitivity and Plasma Insulin [J].
Asare-Bediako, Isaac ;
Paszkiewicz, Rebecca L. ;
Kim, Stella P. ;
Woolcott, Orison O. ;
Kolka, Cathryn M. ;
Burch, Miguel A. ;
Kabir, Morvarid ;
Bergman, Richard N. .
DIABETES, 2018, 67 (08) :1495-1503
[8]  
AUTHIER F, 1994, J BIOL CHEM, V269, P3010
[9]  
Authier F, 1996, CLIN INVEST MED, V19, P149
[10]  
BACKER JM, 1990, J BIOL CHEM, V265, P14828